Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 dichloride for symptomatic bone metastases from breast cancer
2025-524208-31-00Phase 2Authorised
- Sponsor
- Policlinico Paolo Giaccone
- Start
- Jun 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of radium-223 dichloride in breast cancer, sponsored by Policlinico Paolo Giaccone. Primary endpoints: Progression-free survival, Reduction of pain from bone metastases and 1 more. Planned start Jun 2026; status: authorised.
02
Drugs
radium-223 dichloride
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-524208-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524208-31-00.